Dabigatran: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
==[[Dabigatran Etexilate Mesylate|Dabigatran Etexilate Mesylate]]== | ===''[[Dabigatran Etexilate Mesylate|Dabigatran Etexilate Mesylate]]''=== | ||
* [[Pradaxa|Pradaxa]] | * [[Pradaxa|Pradaxa]] | ||
| Line 12: | Line 12: | ||
==Category== | ==Category== | ||
Anticoagulant,Direct thrombin (II) inhibitor | |||
{{Antithrombotics}} | {{Antithrombotics}} | ||
Revision as of 19:20, 27 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Dabigatran Etexilate Mesylate
Overview
Dabigatran is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications, for some of which it may replace warfarin as the preferred anticoagulant. It is orally administered as the prodrug dabigatran etexilate (planned trade names Rendix and Pradaxa). It was developed by pharmaceutical company Boehringer-Ingelheim.
Category
Anticoagulant,Direct thrombin (II) inhibitor